货号:A724445
同义名:
GC7 (sulfate); N1-Guanyl-1,7-diaminoheptane
GC7 Sulfate是一种针对脱氧嘌呤合成酶 (DHPS) 的抑制剂,具有抗病原体的活性,应用于抗感染药物的开发中。
There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | DNA synthesis ↓ ↑ | helicase ↓ ↑ | RdRp ↓ ↑ | ribonucleotide reductase ↓ ↑ | tRNA synthetase ↓ ↑ | YB-1 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fexinidazole | ✔ | 98% | |||||||||||||||||
Daptomycin | ✔ | 98% | |||||||||||||||||
Blasticidin S·HCl | ✔ | 98% | |||||||||||||||||
Metronidazole | ✔ | 98% | |||||||||||||||||
Daunorubicin HCl |
+++
DNA synthesis, Ki: 20 nM |
98% | |||||||||||||||||
Triglycidyl isocyanurate | ✔ | p53 | 98+% | ||||||||||||||||
Nedaplatin | ✔ | 99%+ | |||||||||||||||||
Oxolinic acid | ✔ | 98+% | |||||||||||||||||
Bendamustine | ✔ | 98+% | |||||||||||||||||
Trifluridine | ✔ | 98% | |||||||||||||||||
Robinetin | ✔ | 99%+ | |||||||||||||||||
Carboplatin | ✔ | 99% | |||||||||||||||||
Cidofovir | ✔ | 99% | |||||||||||||||||
Cisplatin | ✔ | 99% | |||||||||||||||||
Cytarabine |
++++
DNA synthesis, IC50: 16 nM |
98% | |||||||||||||||||
Acelarin |
++++
DNA synthesis, EC50: 0.2 nM |
99%+ | |||||||||||||||||
Oxaliplatin | ✔ | 98% | |||||||||||||||||
YK-4-279 | ✔ | 99%+ | |||||||||||||||||
ML216 |
+
BLMfull-length, IC50: 2.98 μM BLM636-1298, IC50: 0.97 μM |
99%+ | |||||||||||||||||
RK-33 | ✔ | 98% | |||||||||||||||||
Brr2-IN-3 | ✔ | 99%+ | |||||||||||||||||
Phen-DC3 Trifluoromethanesulfonate | ✔ | 95% | |||||||||||||||||
Favipiravir | ✔ | 99% | |||||||||||||||||
Suramin sodium salt |
++
RdRp, IC50: 0.26 μM |
99%+ | |||||||||||||||||
Clofarabine |
++
Ribonucleotide reductase, IC50: 65 nM |
97% | |||||||||||||||||
Didox | ✔ | 98% | |||||||||||||||||
(E)-3-AP | ✔ | 99% | |||||||||||||||||
Halofuginone |
+++
prolyl-tRNA synthetase, Ki: 18.3nM |
99%+ | |||||||||||||||||
BC-LI-0186 |
+++
Leucyl-tRNA synthetase, IC50: 46.11 nM Leucyl-tRNA synthetase, Kd: 42.1 nM |
98% | |||||||||||||||||
SU056 |
+
YB-1, IC50: 1.73 μM |
98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
Concentration | Treated Time | Description | References | |
Human THP-1 macrophages | 20 µM | 48 hours | Inhibited M2-like macrophage polarization | Cell Death Dis. 2023 Aug 31;14(8):579 |
Murine bone marrow-derived macrophages (BMDMs) | 20 µM | 48 hours | Inhibited M2-like macrophage polarization | Cell Death Dis. 2023 Aug 31;14(8):579 |
Human oral squamous cell carcinoma cells (Cal27) | 10, 20, 40 µM | 48 hours | Inhibited cell proliferation and colony formation | Cell Death Dis. 2023 Aug 31;14(8):579 |
LoVo | 100 μM | 24, 48, and 72 h | Inhibition of CRC cell proliferation and EIF5A hypusination | Cell Death Dis. 2020 Dec 10;11(12):1045 |
SW480 | 100 μM | 24, 48, and 72 h | Inhibition of CRC cell proliferation and EIF5A hypusination | Cell Death Dis. 2020 Dec 10;11(12):1045 |
HCT116 | 100 μM | 24, 48, and 72 h | Inhibition of CRC cell proliferation and EIF5A hypusination | Cell Death Dis. 2020 Dec 10;11(12):1045 |
HT29 | 100 μM | 24, 48, and 72 h | Inhibition of CRC cell proliferation and EIF5A hypusination | Cell Death Dis. 2020 Dec 10;11(12):1045 |
B16-F10 cells | 2.0 μM | 24 hours | Evaluate the effect of GC-7 on the survival rate of B16-F10 cells | Adv Sci (Weinh). 2024 Sep;11(33):e2402450 |
SK-MEL-28 cells | 2.0 μM | 24 hours | Evaluate the effect of GC-7 on the survival rate of SK-MEL-28 cells | Adv Sci (Weinh). 2024 Sep;11(33):e2402450 |
A375 cells | 2.0 μM | 24 hours | Evaluate the effect of GC-7 on the survival rate of A375 cells, results showed GC-7 had a smaller impact on cell survival at the same concentration | Adv Sci (Weinh). 2024 Sep;11(33):e2402450 |
Mouse renal proximal convoluted tubule cells (PCT) | 30 µM | 24 hours | GC7 treatment induced a decrease in eIF5A hypusination, shifting cell metabolism from oxidative phosphorylation to glycolysis, increasing glucose consumption and lactate efflux, while decreasing glucose uptake. | Cell Death Dis. 2021 Mar 17;12(4):283 |
CD4 deficient PBMCs | 100μM/mL | 7 days | To assess the ability of CD4 deficient PBMCs to convert into CD4+CD25+FOXP3+ Tregs under GC7+anti-DLL4 treatment. Results showed that 20.3±3.1% of CD8+ T cells converted into CD4+ T cells, with 45.6±8.8% further differentiating into CD4+CD25+FOXP3+ Tregs. | Immunotargets Ther. 2025 Mar 13;14:205-226 |
CD4+CD25− T cells | 100μM/mL | 7 days | To induce the conversion of CD4+CD25− T cells into CD4+CD25+FOXP3+ Tregs and evaluate their suppressive function. Results showed that 63.4±5.4% of CD4+CD25− T cells converted into CD4+CD25+ T cells with significant proliferative capacity. | Immunotargets Ther. 2025 Mar 13;14:205-226 |
cortical neurons | 30 μM | 12 hours | GC7 significantly reduced neuronal death induced by oxygen-glucose deprivation (OGD) and protected mitochondrial membrane potential and reduced ROS generation | J Cereb Blood Flow Metab. 2021 May;41(5):1080-1090 |
Renal proximal convoluted tubule cells (PCT) | 30 μM | 8-hour pretreatment, exposed to anoxia 24 hours later | GC7 pretreatment significantly enhanced PCT cell survival under anoxia, reduced CHOP nuclear translocation, and modulated ER stress pathways (increased xbp1 splicing and BiP expression, decreased eIF2α phosphorylation). | Cells. 2023 Jan 25;12(3):409 |
HTR-8/SVneo cells | 160 µM | 24 hours | Inhibits proliferation, migration and invasion of HTR-8 cells | Cell Death Dis. 2018 Sep 11;9(9):926 |
Administration | Dosage | Frequency | Description | References | ||
C3H mice | Syngeneic orthotopic tongue OSCC model | Intraperitoneal injection | 20 mg/kg (first 3 days), 10 mg/kg (subsequently every 2 days) | Once daily for the first 3 days, then every 2 days for 14 days | Inhibited tumor growth and M2-like TAM infiltration | Cell Death Dis. 2023 Aug 31;14(8):579 |
Nude mice | A375 cell xenograft model | Intraperitoneal injection | 40 mg/kg | Every 3 days for 18 days | Evaluate the inhibitory effect of GC-7 on tumor growth, results showed GC-7 had a weaker inhibitory effect on tumor growth | Adv Sci (Weinh). 2024 Sep;11(33):e2402450 |
Nude mice | HCT116 xenograft model | Intraperitoneal injection | 4 mg/kg | Daily for 15 days | GC7 significantly decreased tumor growth and EIF5A hypusination | Cell Death Dis. 2020 Dec 10;11(12):1045 |
Mouse | C57BL/6 male mice | Intraperitoneal injection | 3 mg/kg | Once daily for 3 days | GC7 treatment reduced eIF5A hypusination in the kidney, decreased GLUT1 protein expression, and increased urinary glucose and lactate excretion without affecting renal function. | Cell Death Dis. 2021 Mar 17;12(4):283 |
C57BL/6J mice | Transient focal cerebral ischemia (tFCI) model | Intraperitoneal injection | 3 mg/kg | Pretreatment: single or three injections at 48, 24, 2 h before; Post-treatment: sequential injections at 2 h, 2d, 4d, 7d, 10d, 14d, and 17d after | GC7 significantly reduced brain infarct volume and improved motor and cognitive functional recovery | J Cereb Blood Flow Metab. 2021 May;41(5):1080-1090 |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.70mL 0.74mL 0.37mL |
18.49mL 3.70mL 1.85mL |
36.99mL 7.40mL 3.70mL |
CAS号 | 150417-90-6 |
分子式 | C8H22N4O4S |
分子量 | 270.35 |
SMILES Code | NC(NCCCCCCCN)=N.O=S(O)(O)=O |
MDL No. | MFCD31619261 |
别名 | GC7 (sulfate); N1-Guanyl-1,7-diaminoheptane |
运输 | 蓝冰 |
InChI Key | MDDOWYFCKAAANU-UHFFFAOYSA-N |
Pubchem ID | 131842088 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, 2-8°C |
溶解方案 |
H2O: 3 mg/mL(11.1 mM)
|